Richard Giroux Sells 24,000 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) Stock

MeiraGTx Holdings plc (NASDAQ:MGTX) CFO Richard Giroux sold 24,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the completion of the sale, the chief financial officer now directly owns 849,947 shares of the company’s stock, valued at $5,346,166.63. This represents a 2.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

MeiraGTx Trading Down 5.8 %

Shares of MGTX stock opened at $6.04 on Thursday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. MeiraGTx Holdings plc has a fifty-two week low of $3.85 and a fifty-two week high of $7.37. The company has a market cap of $472.03 million, a PE ratio of -4.99, a P/E/G ratio of 0.34 and a beta of 1.26. The stock’s fifty day moving average price is $6.19 and its two-hundred day moving average price is $5.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Knoll Capital Management LLC acquired a new stake in shares of MeiraGTx in the 3rd quarter valued at approximately $5,212,000. Erste Asset Management GmbH acquired a new stake in MeiraGTx in the third quarter valued at approximately $2,795,000. Garden State Investment Advisory Services LLC bought a new stake in shares of MeiraGTx during the third quarter worth $1,636,000. Barclays PLC increased its holdings in MeiraGTx by 107.1% in the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock worth $618,000 after purchasing an additional 76,437 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in MeiraGTx in the fourth quarter valued at about $459,000. Institutional investors own 67.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Chardan Capital reissued a “buy” rating and set a $36.00 price target on shares of MeiraGTx in a research report on Monday, November 18th. Royal Bank of Canada raised their price target on MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.